Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Eli Lilly and Company’s quarterly profit, reported on Wednesday, topped Wall Street estimates, supported by sales of its Humalog diabetes drug and by lower tax bill.

Eli Lilly shares closed lower for the fifth time in the past eleven trading sessions in New York on Wednesday. It has also been the steepest daily loss since October 2nd. The stock went down 2.22% ($2.44) to $107.40, after touching an intraday low at $101.62, or a price level not seen since August 14th 2018 ($101.27).

Shares of Eli Lilly and Company have retreated 7.19% so far in 2019 compared with a 19.85% gain for the benchmark index, S&P 500 (SPX).

In 2018, Eli Lilly’s stock went up 37.01%, thus, it outperformed the S&P 500, which registered a 6.24% loss.

Eli Lilly’s third-quarter revenue, reported at $5.48 billion, fell short of market consensus of $5.50 billion, mostly because of flat overall sales in the United States.

The two versions of the company’s insulin injection Humalog generated $648.9 million in revenue during the third quarter and also outstripped the median analyst estimate of $645.33 million.

Net income attributable to shareholders was reported at $1.25 billion ($1.37 per share) during the quarter ended on September 30th compared with $1.15 billion ($1.12 per share) in the same period a year earlier.

Meanwhile, earnings per share, which exclude special items, were reported at $1.48 during the third quarter, thus, exceeding the median analyst estimate of $1.41 per share.

Eli Lilly also revised up its full-year 2019 adjusted earnings forecast to a range of $5.75-$5.85 per share from a previously expected range of $5.67-$5.77 per share.

Analyst stock price forecast and recommendation

According to CNN Money, the 11 analysts, offering 12-month forecasts regarding Eli Lilly and Co’s stock price, have a median target of $133.00, with a high estimate of $145.00 and a low estimate of $93.00. The median estimate represents a 23.84% upside compared to the closing price of $107.40 on October 23rd.

The same media also reported that at least 7 out of 14 surveyed investment analysts had rated Eli Lilly and Co’s stock as “Hold”, while other 7 – as “Buy”.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Crude oil futures weekly recap, May 12 – May 16Crude oil futures weekly recap, May 12 – May 16 Crude oil futures logged sizable gains this week, as the crisis in Ukraine bolstered risk premium ahead of the presidential elections next Sunday. Elsewhere, US supplies showed mixed signs, with gasoline demand growing and crude gaining in […]
  • Euro-zone bailout fund to keep banks safeEuro-zone bailout fund to keep banks safe The finance ministers of the Euro-zone agreed to let a bailout fund pump cash directly into struggling banks. That would happen only if countrys governments share the risk by making capital investments in such banks.This strategy of direct […]
  • Forex Market: USD/CAD daily trading outlookForex Market: USD/CAD daily trading outlook Yesterday’s trade saw USD/CAD within the range of 1.2353 - 1.2199. The pair closed 0.67% lower at 1.2254, falling for a third straight day.At 7:19 GMT today USD/CAD was up 0.30% for the day to trade at 1.2291. The cross held in a daily […]
  • USD/ZAR trades near 3-week peak as SA faces severe power cutsUSD/ZAR trades near 3-week peak as SA faces severe power cuts The South African Rand retreated against the US Dollar on Tuesday, as South Africa experienced the most severe power cuts on record.State utility Eskom reinstated the worst rolling blackouts on record, which resulted in up to 12 hours […]
  • Forex Market: EUR/USD daily trading outlookForex Market: EUR/USD daily trading outlook Friday’s trade saw EUR/USD within the range of 1.0801-1.0936. The pair closed at 1.0932, dipping 0.04% on a daily basis. It has been the third drop in the past five trading days. In weekly terms, EUR/USD added 0.66% last week, following a […]
  • Anheuser-Busch InBev SA’s share price up, to acquire Pivovar Samson putting an end to the brand rights battle with BudwarAnheuser-Busch InBev SA’s share price up, to acquire Pivovar Samson putting an end to the brand rights battle with Budwar The biggest beer manufacturer in the world - Anheuser-Busch InBev SA made an official statement, revealing it acquired Pivovar Samson a.s. and is also considering to expand its Budweiser brand. The acquisition of Pivovar Samson puts an end to […]